Jefferies analyst Maury Raycroft maintained a Buy rating on KalVista Pharmaceuticals (KALV – Research Report) on September 9 and set a price target of $44.00. The company’s shares closed last Friday at $15.87.
According to TipRanks, Raycroft is a 3-star analyst with an average return of 3.1% and a 38.38% success rate. Raycroft covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Mirati Therapeutics, and Kezar Life Sciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for KalVista Pharmaceuticals with a $43.33 average price target, representing a 173.03% upside. In a report released on September 9, H.C. Wainwright also reiterated a Buy rating on the stock with a $48.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $21.00 and a one-year low of $8.00. Currently, KalVista Pharmaceuticals has an average volume of 215K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.
Read More on KALV:
- Jefferies Remains a Buy on Reata Pharmaceuticals (RETA)
- JPMorgan Chase & Co. (JPM) Receives a Rating Update from a Top Analyst
- Analysts Offer Insights on Technology Companies: Apple (AAPL), Zscaler (ZS) and Sprinklr (CXM)
- Analysts Offer Insights on Healthcare Companies: Immatics (IMTX), Biogen (BIIB) and Bicycle Therapeutics (BCYC)
- SVB Securities Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)
